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Arsenic in drinking water is a major environ-
mental carcinogen. Worldwide, millions of 
people suffer debilitating health effects from 
inorganic arsenic exposure, including cancer 
and vascular, pulmonary, hematologic, neuro-
logic, and developmental disorders [Heck et al. 
2008a; International Agency for Research on 
Cancer (IARC) 2004]. In the United States, 
an estimated 13 million people are exposed 
to arsenic concentrations that exceed the U.S. 
Environmental Protection Agency’s (EPA) 
maximum contaminant level of 10 ppb (U.S. 
EPA 2001).
An increase in the incidence of skin, blad-
der, and lung cancers at high arsenic con-
centrations is well established (IARC 2004). 
However, the cancer risk from exposure to 
lower levels (< 100 µg/L) of arsenic is largely 
unknown. The results from other studies have 
been inconsistent (Ahsan et al. 2000; Chen 
et al. 2004; Ferreccio et al. 1998; Karagas 
et al. 2001, 2002; Lamm et al. 2004; Lewis 
et al. 1999), perhaps due, in part, to expo-
sure variation in settings where people have 
access to noncontaminated water sources. 
Inconsistencies in results may also be related to 
a lack of information on individual cofactors, 
such as smoking or relevant health conditions, 
or to regional differences in factors associated 
with arsenic susceptibility, such as nutrition 
(Heck et al. 2007, 2009).
Lung cancer is the leading cause of cancer- 
related mortality in the United States and 
worldwide. IARC (2004) has classified arse-
nic as a group 1 carcinogen for lung cancer 
(IARC 2004). This assessment was based 
on studies in which arsenic exposure was 
inferred by using area of residence or the arse-
nic concentration the in well water rather 
than using an individual biomarker of expo-
sure (Chen et al.1985, 1986, 1988a, 1988b; 
Chen and Wang 1990; Chiou et al. 1995; 
Ferreccio et al. 2000; Hinwood et al. 1999; 
Hopenhayn-Rich et al. 1998; Lewis et al. 
1999; Nakadaira et al. 2002; Rivara et al. 
1997; Smith et al. 1998; Tsai et al. 1999; 
Tsuda et al. 1995; Wu et al. 1989). The stud-
ies not included in the IARC evaluation and 
those that have been published since also 
have been based on local or regional well-
water concentrations (Baastrup et al. 2008; 
Chen et al. 2004; Ferreccio et al. 1998; Guo 
2004; Han et al. 2008; Marshall et al. 2007; 
Mostafa et al. 2008; Smith et al. 2006).
The use of a biomarker of arsenic expo-
sure may help to improve the assessment of 
low-dose health effects, including cancer inci-
dence (Karagas et al. 2002). Trivalent inor-
ganic arsenic binds to the sulfhydryl groups 
in nail keratin cells and thus makes toenail 
arsenic a reasonable measure of arsenic expo-
sure. Depending on the toe and the speed of 
nail growth, toenail measurements represent 
exposures that occurred 3–12 months before 
sample collection. This finding has been found 
to be relatively stable over time (Garland et al. 
1993). In this study, we used toenail arsenic 
concentration as a biomarker of exposure to 
examine the risk of lung cancer among persons 
in the U.S. population who had been exposed 
to low levels of arsenic in drinking water.
Materials and Methods
The New England Lung Cancer Study 
(NELCS), a population-based case–control 
study of lung cancer, was conducted in seven 
New Hampshire counties (Belknap, Carroll, 
Cheshire, Coos, Grafton, Merrimack, and 
Sullivan) and in three Vermont counties 
(Orange, Windham, and Windsor). We used 
the New Hampshire State Cancer Registry, 
the Dartmouth-Hitchcock Tumor Registry 
of the Norris Cotton Cancer Center, and the 
Dartmouth-Hitchcock Medical Center in 
Lebanon, New Hampshire, to identify per-
sons from 2005 to 2007 who had received a 
clinical diagnosis of lung cancer. We obtained 
the names of cases within 1 to 6 months of 
their initial diagnosis. Cases who had histo-
logically confirmed primary incident lung 
cancer (World Health Organization 2000), 
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Ba c k g r o u n d: Little is known about the carcinogenic potential of arsenic in areas with low to 
moderate concentrations of arsenic (< 100 µg/L) in drinking water.
oBjectives: We examined associations between arsenic and lung cancer.
Me t h o d s : A population-based case–control study of primary incident lung cancer was conducted 
in 10 counties in two U.S. states, New Hampshire and Vermont. The study included 223 lung can-
cer cases and 238 controls, each of whom provided toenail clippings for arsenic exposure measure-
ment by inductively coupled–plasma mass spectrometry. We estimated odds ratios (ORs) of the 
association between arsenic exposure and lung cancer using unconditional logistic regression with 
adjustment for potential confounders (age, sex, race/ethnicity, smoking pack-years, education, body 
mass index, fish servings per week, and toenail selenium level).
re s u l t s: Arsenic exposure was associated with small-cell and squamous-cell carcinoma of the lung 
[OR = 2.75; 95% confidence interval (CI), 1.00–7.57] for toenail arsenic concentration ≥ 0.114 µg/g, 
versus < 0.05 µg/g. A history of lung disease (bronchitis, chronic obstructive pulmonary disease, 
or fibrosis) was positively associated with lung cancer (OR = 2.86; 95% CI, 1.39–5.91). We also 
observed an elevated risk of lung cancer among participants with a history of lung disease and toenail 
arsenic ≥ 0.05 µg/g (OR = 4.78; 95% CI, 1.87–12.2) than among individuals with low toenail 
arsenic and no history of lung disease.
co n c l u s i o n: Although this study supports the possibility of an increased risk of specific lung 
  cancer histologic types at lower levels of arsenic exposure, we recommend large-scale population-
based studies.
key w o r d s : arsenic, bronchitis, chronic obstructive pulmonary disease, lung cancer, lung diseases, 
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were between 30 and 74 years of age, resided 
in one of the 10 study counties, were alive at 
first contact, had a working telephone number, 
and were able to communicate in English. Of 
the 454 eligible cases, 24 (5%) could not be 
reached because of an inaccurate address or 
phone number, 52 (11%) were too ill to be 
interviewed, and 101 (22%) refused to par-
ticipate, which yielded 277 subjects and a 61% 
participation rate.
Control participants were identified using 
a commercial database from Experian for the 
contiguous 10-county study area for the period 
2005–2006. For each potential control, the 
database contained the full name, date of birth 
(or estimated age), address, sex, and telephone 
number. Using a marginal count comparison 
with U.S. Census Bureau data for the same 
time period, we identified 73.4% of women 
and 72.4% of men in the NELCS study area 
in the commercial database. The eligibility of 
the controls was based on the same criteria as 
that used for cases except for the presence of 
lung cancer. Controls were randomly selected 
from the commercial database and frequency 
matched to lung cancer cases within 5-year age 
group and by sex. Of the 547 eligible controls, 
123 (22%) could not be reached because of 
inaccurate address or phone number, 11 (2%) 
were too ill to be interviewed, and 162 (30%) 
refused participation. A total of 251 controls 
completed the interview for a 46% participa-
tion rate. Because self-reported home owner-
ship was somewhat higher among controls 
than among cases, we ran all models with 
and without a variable for home ownership as 
well as educational attainment and household 
income to account for potential differences in 
these socioeconomic variables.
Study protocol. A letter describing the study 
was sent to potential cases and controls inform-
ing them of the study and mentioning that a 
study interviewer would be contacting them by 
telephone within 2 weeks. A prepaid postcard 
was included that requested an updated phone 
number if the number provided was no longer 
valid. At the initial telephone contact, the indi-
vidual’s name and age were confirmed, verbal 
permission obtained, and an interview date 
requested. At the in-person interview, writ-
ten informed consent was obtained from all 
participants before participation. The study 
complied with all applicable requirements of 
the Dartmouth College’s Committee for the 
Protection of Human Subjects, the Norris 
Cotton Cancer Center, and the State of New 
Hampshire for obtaining case names from the 
New Hampshire State Cancer Registry. Most 
case and control interviews occurred in the par-
ticipant’s home; some cases were interviewed 
in the Norris Cotton Cancer Center or other 
location at the participant’s request. All in-
person interviews were conducted by trained 
interviewers using a structured questionnaire 
on demographic, lifestyle and medical history; 
a 121-item, validated food frequency ques-
tionnaire (Salvini et al. 1989); and a lifetime 
residential history calendar. The following bio-
logical specimens were requested at the inter-
view: a 20-mL blood sample (32% of blood 
samples from cases were obtained before initia-
tion of therapy), toenail clippings, an oral buc-
cal brushing, and a Scope (Procter & Gamble 
Co., Cincinnati, OH, USA) mouthwash sam-
ple, which was used as a source of oral cells for 
genomic DNA isolation from those unable or 
unwilling to provide a blood sample. In this 
study, we used only toenail samples and ques-
tionnaire data for the arsenic analysis. 
Of the 528 participants, we excluded from 
the analysis 62 who did not provide a toenail 
sample and 2 (< 1%) whose toenail selenium 
could not be analyzed. An additional 3 sub-
jects (< 1%) were excluded because of missing 
information on smoking or weight. The final 
sample size was 461 participants.
Toenail arsenic analyses. Toenails were 
thoroughly washed (and sonicated) with 
acetone and Triton-X 100 and rinsed five 
times in deionized water to remove exoge-
nous contamination. The nail sample was acid 
digested in HNO3 (Optima; Fisher Scientific, 
St. Louis, MO, USA) using microwave tech-
niques (Microwave Accelerated Reaction 
System 5; CEM Corp., Mathews, NC, USA).
Diluted aliquots of the digested toe-
nail samples were analyzed by collision cell 
inductively coupled plasma–mass spectrom-
etry (7500c, Agilent Technologies, Inc., Santa 
Clara, CA, USA). Quality control included 
assessing the percent recovery of the GBW 
07601 hair standard reference material 
(National Analysis Center, Beijing, China) 
with a certified arsenic value of 0.28 ± 0.04 
mg/kg. Our repeated analysis of this refer-
ence material (n = 40 > 2 years) gave a value 
of 0.235 ± 0.038 (2σ). We also ran repeated 
analy  ses of a second source matrix-spiked 
sample (as an initial calibration check and a 
continuing calibration check) at a frequency 
of every 10 samples and control criteria of 
80–120% recovery. Analysis blanks were run 
at a frequency of every 20 samples. Digestion 
blanks were routinely analyzed and were gener-
ally low (< 10 ng/L in the 4× diluted samples). 
The mean plus 3 times the standard deviation 
(SD) of the digestion blanks was used to deter-
mine method detection. The detection limits 
are a function of both the method detection 
limit and the mass of the nail available for the 
digestion. The average sample specific detec-
tion limit for arsenic was 0.003 µg/g. For four 
persons, the measured arsenic fell below this 
limit, and these individuals were assigned an 
arsenic value of 0.0015.
Statistical analyses. We analyzed the 
demograhic and health characteristics of the 
cases and controls and report the odds ratios 
(ORs) of the diseases associated with these 
characteristics. Geometric means of toenail 
arsenic concentrations were determined and 
compared using analysis of variance. Arsenic 
exposure has been linked to bronchitis, chronic 
obstructive pulmonary disease (COPD), fibro-
sis, diabetes, and cardiovascular disease (IARC 
2004; Mazumder et al. 2005; Smith et al. 
2006; States et al. 2009; von Ehrenstein et al. 
2005). To describe any potential risk for these 
conditions, we provided geometric means for 
toenail arsenic concentrations among persons 
with and without these diseases. To describe 
the possible arsenic sources in this population, 
we also determined arsenic concentrations 
from drinking water sources and from other 
potential exposure routes such as previous 
employment in farmwork or woodworking.
We used unconditional logistic regression 
analyses to examine the relative risk of lung 
cancer with toenail arsenic levels. In the main 
analyses, we categorized toenail arsenic into 
four levels: < 0.05 µg/g, 0.05 to < 0.0768 µg/g, 
0.768 to < 0.1137 µg/g, and ≥ 0.1137 µg/g. 
The rationale for this stratification was based on 
results from a study of well water and toenail 
arsenic from participants in the same region 
where Karagas et al. (2000) observed that indi-
viduals with toenail arsenic < 0.05 µg/g were 
almost uniformly exposed to drinking water 
arsenic concentrations of < 1 µg/L. Above that 
point, we categorized the participants into 
three levels based on the arsenic concentra-
tions among the controls. Because arsenic has 
been reported to be associated with squamous-
cell and small-cell carcinoma, we also analyzed 
lung cancer risk by histology (Guo et al. 2004; 
Mostafa et al. 2008).
Variables considered for inclusion in the 
logistic regression models were those previously 
associated with arsenic, with lung cancer inci-
dence, and with interindividual variation in 
nail growth (Ahsan et al. 2006; Slotnick and 
Nriagu 2006). The analyses also included age, 
sex, race/ethnicity, tobacco smoking (pack-
years), educational attainment (< high school, 
high school, > high school), body mass index 
(BMI: < 18.5, 18.5 to < 25, ≥ 25), prior self-
reported history of arsenic-related lung disease 
(bronchitis, COPD, or fibrosis), servings of 
fish per week, and selenium intake (quartiles of 
toenail concentration; milligrams per kilogram). 
We included selenium in the model because 
it has been linked to cancer prevention in the 
presence of arsenic (Chen et al. 2007). Fish 
have trace levels of arsenic, mostly in organic 
form, but may also have trace levels of inorganic 
arsenic, which in humans, has been linked to 
tobacco use and to toenail arsenic concentra-
tion (Heck et al. 2008b; Slotnick and Nriagu 
2006). Eleven subjects did not complete the 
food frequency questionnaire and were assigned 
a weekly fish intake equivalent to the mean in 
the overall sample (mean, 1.75 servings).Heck et al.
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Because of potential synergistic effects 
between arsenic and smoking and between 
arsenic and lung disease, we present the 
results of models that examined these possible 
interaction effects (Chen et al. 2004; Parvez 
et al. 2008). We also examined whether a 
history of asthma was associated with arsenic 
and lung cancer; we found no association and 
left this variable out of final models. We also 
observed no evidence of an interaction effect 
between arsenic and selenium on lung cancer 
risk (p = 0.4).
Results
Study subjects were similar in age and sex 
(Table 1). The mean age (± SD) was 61.9 ± 
9.1 years for cases and 61.0 ± 10.2 years for 
controls. Controls smoked less than cases, and 
more controls than cases had received edu-
cation beyond high school. Toenail arsenic 
concentrations for the entire study population 
ranged from 0.007 to 1.57 µg/g. The distri-
bution of toenail arsenic concentrations was 
skewed: 29.1% had arsenic at < 0.05 µg/g, 
42.3% between 0.05 and 0.1 µg/g, 18.4% 
between 0.1 and 0.15 µg/g, 5.2% between 
0.15 and 0.2 µg/g, 4.6% between 0.2 and 
0.7 µg/g, and < 1% (two subjects) had arsenic 
> 1 µg/g. Toenail arsenic concentrations dif-
fered by age, with the highest concentrations 
among persons < 70 years of age (Table 1). 
Toenail arsenic concentration was positively 
associated with fish servings per week and 
in controls, it was positively associated with 
toenail selenium concentration. The average 
length of time at the current residence did not 
differ between cases (mean, 17.2 years) and 
controls (mean, 16.9 years).
In Table 2, we describe prior lung dis-
ease, cardiovascular disease, adult-onset diabe-
tes, and potential sources of arsenic exposure 
in the study population in relation to mean 
arsenic levels. Among controls, those who 
received their water from a nonfiltered well or 
spring had higher mean toenail arsenic con-
centrations than did those who drank filtered 
water. Cases who owned their own homes 
had higher mean arsenic than did cases who 
were not homeowners.
In the multiple regression analyses, higher 
toenail arsenic levels were associated with 
small-cell carcinoma and squamous-cell carci-
noma lung cancer (Table 3). We also observed 
an increased risk of lung cancer among those 
who reported a prior history of lung disease 
(OR = 3.2). With stratification by histology, 
we noted that an increased risk of lung cancer 
was driven primarily by small-cell carcinoma 
cases, although the number of cases in each 
histologic group was small (data not shown).
When we examined all lung cancers com-
bined, we found no evidence of an inter-
action effect between arsenic exposure and 
cigarette smoking in relation to lung cancer 
risk (Table 4). When we stratified by self- 
reported history of lung disease, we observed 
an increased risk of lung cancer among 
patients with lung disease and toenail arsenic 
concentrations > 0.05 µg/g. We obtained sim-
ilar results when we excluded the two patients 
with toenail arsenic > 1 µg/g (data not shown).
Because home ownership was more com-
mon among the cases in the Experian database 
(80%) than among the cases in the study area 
(by county, 68–78%) (U.S. Census Bureau 
2008), we examined whether effect estimates 
were similar when we limited the analyses to 
homeowners (n = 388, 85%), which yielded 
similar results to those seen in the overall find-
ings (data not shown).
Discussion
For persons in this study population who were 
exposed to low to moderate levels of arsenic 
Table 1. Characteristics of the study population and toenail arsenic concentrations.
Arsenic concentration (µg/g) Crude odds of  
lung cancer associated 
with characteristic
[OR (95% CI)]
Cases (n = 223)  Controls (n = 238)
Characteristic No. (%) GM (SE) p-Value No. (%) GM (SE) p-Value
Sex 0.3 0.8
  Male 100 (44.8) 0.063 (0.004) 97 (40.8) 0.073 (0.005) 1.00
  Female 123 (55.2) 0.071 (0.006) 141 (59.2) 0.074 (0.004) 0.85 (0.58–1.22)
Age (years) 0.4 0.3
  30–49 24 (10.8) 0.081 (0.013) 34 (14.3) 0.076 (0.009) 1.00
  50–59 56 (25.1) 0.071 (0.007) 60 (25.2) 0.079 (0.007) 1.32 (0.70– 2.50)
  60–69 90 (40.4) 0.069 (0.006) 82 (34.5) 0.076 (0.006) 1.55 (0.85– 2.84)
  ≥ 70 53 (23.8) 0.054 (0.006) 62 (26.1) 0.063 (0.006) 1.21 (0.64– 2.29)
Race/ethnicity 0.3 0.4
  White non-Hispanic 213 (95.5) 0.087 (0.022) 233 (97.9) 0.058 (0.018) 1.00
  All other ethnicities 10 (4.5) 0.066 (0.004) 5 (2.1) 0.076 (0.003) 2.19 (0.74– 6.50)
Educational attainment 0.09 0.1
  High school graduate or less 132 (59.2) 0.062 (0.004) 78 (32.8) 0.066 (0.005) 1.65 (1.37– 1.97)
  Technical school, college, or more 91 (40.8) 0.074 (0.006) 160 (67.2) 0.077 (0.004) 1.00 
BMI 6 months before interview 0.4 0.09
  17.2–24.9 89 (39.9) 0.062 (0.005) 77 (32.4) 0.081 (0.007) 1.00
  25–29.9 72 (32.3) 0.073 (0.007) 78 (32.8) 0.071 (0.006) 0.80 (0.51–1.24)
  ≥ 30 62 (27.8) 0.066 (0.007) 83 (34.9) 0.068 (0.005) 0.65 (0.41–1.01)
Smoking (pack-years) 0.9 0.7
  0 (never-smoker) 12 (5.4) 0.065 (0.015) 100 (42.0) 0.072 (0.005) 1.00
  < 20 19 (8.5) 0.064 (0.011) 69 (29.0) 0.080 (0.007) 2.29 (1.05–5.03)
  21–40 49 (22.0) 0.072 (0.008) 36 (15.1) 0.064 (0.008) 11.3 (5.43–23.7)
  ≥ 41 143 (64.1) 0.065 (0.004) 33 (13.9) 0.075 (0.009) 36.1 (17.8–73.3)
Servings of fish (times per week) 0.03 0.03
  Never or < 1 89 (39.9) 0.057 (0.005) 88 (37.0) 0.070 (0.005) 1.00
  1 to < 2 84 (37.7) 0.065 (0.005) 71 (29.8) 0.069 (0.006) 1.17 (0.76– 1.80)
  2 to < 4 32 (14.4) 0.092 (0.013) 59 (24.8) 0.079 (0.007) 0.54 (0.32–0.90)
  ≥ 4 18 (8.1) 0.085 (0.015) 20 (8.4) 0.088 (0.014) 0.89 (0.44–1.79)
Selenium quartiles (toenail concentration, mg/kg) 0.6 0.01
  0.05–0.7644  96 (43.0) 0.066 (0.005) 59 (24.8) 0.056 (0.005) 1.00
  0.7645–0.8901  48 (21.5) 0.062 (0.007) 60 (25.2) 0.077 (0.007) 0.49 (0.30– 0.81)
  0.8902–1.075  47 (21.1) 0.066 (0.008) 60 (25.2) 0.076 (0.007) 0.48 (0.29– 0.79)
  1.076–5.857  32 (14.3) 0.077 (0.011) 59 (24.8) 0.087 (0.008) 0.33 (0.19– 0.57)
Abbreviations: GM, geometric mean; CI, confidence interval. p-Values compare mean arsenic concentrations within groups.Arsenic and lung cancer in New England
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from drinking water, we observed an increased 
risk of small-cell carcinoma and squamous-cell 
carcinoma lung cancer among participants 
with higher arsenic concentrations in toe-
nails. Because of the small sample size of this 
study, we recommend that our findings be 
interpreted with caution. Not all studies have 
observed a varying presentation of histologic 
types in the presence of arsenic (Chen et al. 
2004). However, a higher risk of squamous-
cell carcinoma was observed in Bangladesh, 
a region with high concentrations of arse-
nic in the drinking water (up to 366 µg/L) 
(Mostafa et al. 2008). Several case reports, 
occupational studies, and a published study on 
drinking water from Taiwan have all linked 
arsenic exposure to small-cell carcinoma of 
the lung (Guo et al. 2004; Heddle and Bryant 
1983; Kusiak et al. 1993; Lee and Bebb 2005; 
Pershagen et al. 1987).
Because we did not collect samples of each 
participant’s drinking water, we were unable 
to report the risk associated with specific 
arsenic concentrations in well water. A geo-
logic survey of the region found that 28% of 
private wells in New Hampshire and 6.7% 
of wells in Vermont have arsenic concentra-
tions > 5 µg/L (Ayotte et al. 2006). Toenail 
arsenic has been correlated with well-water 
arsenic concentrations in New Hampshire and 
in areas with higher levels of arsenic (Karagas 
et al. 2000; Kile et al. 2007). At lower doses, 
toenail arsenic concentrations are less likely to 
be correlated with concentrations of arsenic in 
drinking water due, most likely, to contribu-
tions from other exposure sources. A sepa-
rate investigation of subjects from the same 
region found that subjects with toenail arsenic 
between 0.05 and 0.5 µg/g had water arse-
nic concentrations between 1 and 100 µg/L 
(Karagas et al. 2000). Besides drinking water 
exposure, subjects also may have been exposed 
to trace amounts of arsenic from dietary 
sources, tobacco, or airborne particle inhala-
tion. We do not anticipate strong effects from 
these other sources, because we accounted for 
some other exposure sources, such as fish and 
smoking, in our multivariate analysis.
We also observed an increased risk of 
lung cancer among participants who reported 
a prior history of nonmalignant lung disease 
(bronchitis, COPD, or fibrosis). A number of 
previous studies have linked arsenic exposure 
to chronic lung diseases, including shortness 
of breath, chest sounds, chronic bronchitis, 
bronchiectasis, COPD, and interstitial fibro-
sis (Guha Mazumder 2007; Mazumder et al. 
2005; Milton and Rahman 2002; Milton et al. 
2003; Smith et al. 2006; States et al. 2009). 
The reported concentrations of water arse-
nic concentrations in these studies were as 
high as > 300 µg/L (Mazumder et al. 2005), 
> 400 µg/L (Guha Mazumder 2007), or 
1,000 µg/L (Milton and Rahman 2002). In 
developing country settings with a wide range of 
arsenic concentrations in drinking water, dose–
response effects have been observed between 
arsenic levels and chronic cough among both 
smokers and nonsmokers (Guha Mazumder 
2007; Smith et al. 2006). Although drinking 
water arsenic increases both lung disease and 
lung cancer rates within the same population 
(Smith et al. 2006), to our knowledge, no pre-
vious studies have examined a potential syner-
gistic effect, perhaps due in part to the ecologic 
Table 2. Toenail arsenic concentrations (µg/g) among study participants, by medical conditions and potential exposure routes.
Arsenic concentration (µg/g) Crude odds of 
lung cancer associated 
with characteristic  
[OR (95% CI)]
Cases (n = 223) Controls (n = 238)
Characteristic No. (%) GM (SE) p-Value No. (%) GM (SE) p-Value
Ever diagnosed with chronic bronchitis 0.2 0.3
  No 188 0.065 (0.004) 225 0.074 (0.003) 1.00
  Yes 35 0.077 (0.010) 13 0.061 (0.012) 3.22 (1.66–6.27)
Ever diagnosed with COPD 0.6 0.2
  No 193 0.067 (0.004) 232 0.074 (0.003) 1.00
  Yes 29 0.062 (0.009) 6 0.052 (0.015) 5.81 (2.36–14.3)
Ever diagnosed with fibrosis 0.5 0.2
  No 219 0.066 (0.004) 236 0.073 (0.003) 1.00
  Yes 2 0.102 (0.057) 1 0.037 (0.026) 2.16 (0.19–23.9)
Ever diagnosed with asthma 0.3 0.4
  No 183 0.065 (0.004) 206 0.072 (0.004) 1.00
  Yes 40 0.074 (0.009) 32 0.081 (0.010) 1.41 (0.85–2.33)
Ever diagnosed with any lung disease (bronchitis,  
COPD, or fibrosis)
0.8 0.09
  No 173 0.066 (0.004) 221 0.075 (0.004) 1.00
  Yes 50 0.068 (0.008) 17 0.057 (0.010) 3.76 (2.09–6.74)
Ever diagnosed with diabetes 0.6 0.09
  No 192 0.067 (0.004) 216 0.075 (0.004) 1.00
  Yes 31 0.062 (0.009) 22 0.059 (0.009) 1.59 (0.89–2.83)
History of cardiovascular disease (ever had coronary  
catheterization, angioplasty, heart attack, or stroke)
0.5 0.5
  No 183 0.067 (0.004) 200 0.074 (0.004) 1.00
  Yes 40 0.062 (0.008) 38 0.068 (0.008) 1.15 (0.71–1.87)
Primary drinking water source 0.8 0.08
  Public water supply, bottled water drinker, or  
  subject never drinks water
124 0.064 (0.005) 111 0.068 (0.005) 1.00
  Well or spring water, filtered 34 0.063 (0.008) 50 0.070 (0.007) 0.61 (0.37–1.01)
  Well or spring water, nonfiltered 64 0.074 (0.007) 77 0.084 (0.007) 0.75 (0.49–1.13)
Owns own home 0.03 0.2
  No 50 0.055 (0.006) 23 0.061 (0.009) 1.00
  Yes 173 0.070 (0.004) 215 0.075 (0.004) 0.43 (0.27–0.68)
Ever employed in farmwork 0.5 0.02
  No 185 0.068 (0.004) 169 0.078 (0.004) 1.00
  Yes 38 0.061 (0.008) 69 0.062 (0.005) 0.50 (0.32–0.79)
Ever employed in woodworking 0.1 0.5
  No 213 0.065 (0.003) 225 0.073 (0.003) 1.00
  Yes 10 0.104 (0.026) 13 0.083 (0.016) 0.81 (0.35–1.89)
Abbreviations: GM, geometric mean; CI, confidence interval.Heck et al.
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design of most studies. Differential effects have 
been observed in inhalation studies. For exam-
ple, Chen and Chen (2002) found that Chinese 
tin miners with silicosis who were exposed to 
arsenic at three mines had an increased risk of 
lung cancer, but not at a fourth mine where 
arsenic concentrations were lower. In a study 
of inhaled arsenic, Taeger et al. (2009) found 
that silicosis appeared to be related to the cell 
type of lung cancer among the uranium work-
ers who were exposed to arsenic. However, it is 
difficult to draw conclusions from these studies 
because the mechanism of arsenic-related lung 
diseases and lung cancer may differ when arse-
nic is inhaled rather than ingested.
We did not observe an independent asso-
ciation between arsenic and lung disease in our 
cases, suggesting that the possible synergistic 
effect should be interpreted with caution. In 
other studies, the presence of respiratory symp-
toms has been reported to be 10–25 times more 
common among persons with arsenical dermato-
sis, even compared with healthy persons living in 
the same region who are likely exposed to similar 
arsenic concentrations in water (Borgono et al. 
1977; De et al. 2004; Guha Mazumder 2007; 
Mazumder et al. 2005; Milton and Rahman 
2002; Milton et al. 2003). We cannot rule out 
the possibility that increased reporting of prior 
lung disease among cases (recall bias) may in 
part explain these results and ours. Nevertheless, 
in a small study, decreases in forced expiratory 
volume and forced vital capacity were more 
pronounced among persons with arsenic- 
related skin cancers than among cancer-free 
controls who also were exposed to arsenic in 
the drinking water (von Ehrenstein et al. 2005). 
However, the greater arsenic concentrations in 
those studies make it difficult to directly com-
pare with our results. We recommend further 
studies in other populations exposed to low or 
moderate levels of arsenic.
Further research is needed to better under-
stand the biologic mechanism by which arse-
nic affects lung function and lung cancer. 
Circulating arsenic is known to be deposited 
in the lung, particularly in epithelial tissue. 
Arsenic has been associated with both obstruc-
tive and restrictive changes in pulmonary 
function (Guha Mazumder 2007). Olsen et 
al. (2008) found evidence for increased lung 
inflammation and inhibition of wound repair 
even at low levels of arsenic exposure. As a 
carcinogen, mechanisms posited for arsenic 
include genetic and epigenetic changes, inhibi-
tion of DNA repair, oxidative stress, apoptosis, 
and modulation of signal transduction path-
ways (Andrew et al. 2006; Huang et al. 2004).
In contrast to other studies (Chen et al. 
2004; Mostafa et al. 2008), we observed no 
interaction between smoking and arsenic 
in lung cancer risk. This difference may be 
explained by the considerably lower arsenic 
concentrations seen in the NELCS area. In the 
study by Mostafa et al. (2008), risk estimates 
for lung cancer did not differ between smokers 
and nonsmokers when arsenic concentrations 
were > 100 µg/L.
A strength of this investigation was the   
population-based study design and data collec-
tion by in-person interview, with detailed infor-
mation sought about prior medical history. To 
our knowledge this study was one of the first 
on arsenic and lung cancer that measured arse-
nic exposure using a biomarker of exposure. In 
developed nations, individuals exposed to arse-
nic in drinking water are likely to have access 
to other water sources. Thus, ecologic analyses 
of arsenic concentrations in drinking water and 
cancer are more likely subject to the ecologic 
fallacy than are studies in developing countries.
A limitation of this study was the response 
rate difference between cases and controls, 
which would be of concern if it led to differ-
ential recruitment according to factors related 
to arsenic exposure. Controls were selected at 
random from persons residing across the study 
area. Arsenic concentrations in well water are 
known to vary considerably within a small geo-
graphic area, with high variation for wells even 
less than 100 m apart (Van Geen et al. 2003). 
Concentrations also can vary considerably 
according to the depth of the well. In addition, 
we did not find an association between case sta-
tus and ZIP code of residence (p = 0.3). Thus, 
we do not anticipate that potential geographic 
differences between cases and controls would 
explain our findings. Given the higher home 
ownership among controls, we also examined 
whether socio  economic status could explain 
the variation seen in arsenic. Among controls, 
arsenic concentrations did not differ by home 
owner  ship (p = 0.2) or by income level (p = 0.9).
Other limitations of this study include 
self-reported demographic and medical infor-
mation that is subject to the biases associated 
with that type of data collection. In addition, 
although participants had generally been liv-
ing at the same address for a considerable time 
period (mean, 17 years), toenail arsenic con-
centrations represent exposures that occurred 
in the previous year, and our results should be 
considered in light of this limitation. Further, 
early life arsenic exposures may be potentially 
relevant to lung cancer development (Smith 
et al. 2006), and the retrospective design of this 
study prohibited us from collecting informa-
tion on earlier exposures. We also did not have 
additional biomarkers, such as urinary arsenic 
or arsenic species (in urine or toenails), which 
could have shed additional light on individual 
arsenic methylation and subsequent cancer 
risk. An analysis of low-level arsenic exposure 
in Slovakia concluded that toenails were more 
predictive than urine of arsenic exposure at low 
concentrations (Wilhelm et al. 2005).
Table 3. Lung cancer in relation to lung disease and arsenic exposure.
All lung cancers (n = 223)
Lung cancer cell types previously 
associated with arsenic (small cell and 
squamous cell) (n = 75)
Measure Cases/controls (n) OR (95% CI)a Cases/controls (n) OR (95% CI)a
History of lung diseaseb
  Never 173/221 1.00 54/221 1.00
  Ever 50/17 2.86 (1.39–5.91) 21/17 3.21 (1.25–8.24)
Toenail arsenic (µg/g)
  < 0.05 65/69 1.00 65/17 1.00
  0.05 to < 0.0768 58/66 1.34 (0.71–2.53) 58/24 2.99 (1.12–7.99)
  0.0768 to < 0.1137 58/44 1.10 (0.55–2.20) 58/13 1.86 (0.62–5.58)
  ≥ 0.1137 57/44 0.89 (0.46–1.75) 57/21 2.75 (1.00–7.57)
aData are ORs and 95% confidence intervals (CIs) by logistic regression. Variables are adjusted for each other, as well 
as for sex, age, race/ethnicity, educational attainment, BMI, fish servings per week, smoking (pack-years), and sele-
nium. bLung disease includes subjects who were ever diagnosed with bronchitis, COPD, or fibrosis.
Table 4. Toenail arsenic concentrations and lung cancer in relation to smoking and lung disease among 
cases (n = 223) and controls (n = 238).
Arsenic 
concentration (µg/g)
All lung cancers
Exposure Cases/ controls OR (95% CI)
Smoking historya 
  Never < 0.05 4/32 1.00
  Never ≥ 0.05  8/67 1.03 (0.28–3.75)
  Ever  < 0.05 65/33 2.86 (0.83–9.80)
  Ever ≥ 0.05  146/106 2.79 (0.87–8.94)
History of lung diseaseb
  Never < 0.05 52/57 1.00
  Never ≥ 0.05  121/164 1.02 (0.62–1.69)
  Ever  < 0.05 17/8 1.31 (0.45–3.84)
  Ever ≥ 0.05  33/9 4.78 (1.87–12.2)
aORs and 95% confidence intervals (CIs) by logistic regression, with adjustment for sex, age, race/ethnicity, educational 
attainment, BMI, lung disease, fish servings per week, smoking (pack-years) and selenium. bModel adjusts for sex, age, 
race/ethnicity, educational attainment, BMI, fish servings per week, smoking (pack-years) and selenium. Lung disease 
includes subjects who were ever diagnosed with bronchitis, COPD, or fibrosis.Arsenic and lung cancer in New England
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Conclusions
We found associations between arsenic expo-
sure and small-cell and squamous-cell carci-
noma of the lung. These findings stress the 
relevance of evaluating the role of arsenic in 
lung cancer development in prospective stud-
ies of populations exposed to all arsenic levels. 
Further studies in persons at low levels of expo-
sure, which include information on health his-
tory, would assist in modifying risk assessment 
for the U.S. population and elsewhere.
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